利培酮口腔崩解片治疗首发精神分裂症的临床疗效

目的探讨利培酮口腔崩解片治疗首发精神分裂症的效果与不良反应。方法将首发精神分裂症患者60例随机分治疗组和对照组，每组30例，分别给予利培酮口腔崩解片（商品名：可同）和利培酮片（商品名：维思通）进行临床对比研究，疗程均为8周。于治疗前及治疗第2、4、8周末采用阳性与阴性症状量表评价临床疗效、副反应量表评价不良反应。结果2组PANSS评分治疗前后均有显著下降，可同治疗组有效率为83.3％，维思通治疗有效率为80.0％，2组比较疗效差异无统计学意义。2组不良反应相似，程度较轻，以锥体外系反应为主，差异无统计学意义。结论利培酮口腔崩解片治疗精神分裂症疗效肯定，不良反应少，依从性好。

A study of risperidone orally disintegrating tablets in the treatment of first-onset chizophrenia

Objective To explore the efficacy and safety of risperidone orally disintegrating tablets in the treatment of first-onset schizophrenia. Methods 60 cases of first- episode schizophrenia patients were randomly divided into treatment group and control group,30 cases in each group were given risperidone orally disintegrating tablets （trade name ： retong） and risperidone tablets （trade name：risperdal） clinical comparative study, treatment of 8 weeks. Before and 4, 8, and 12 weeks after the treatment to evaluat the clinical efficacy by positive and negative symptom scale and the adverse reactions by side effects rating scale. Results The PANSS score of the two groups were decreased significantly before and after treatment , the efficiency of risperidone drally disintegrating tablets group was 83.0% and risperdal group was 80.7% ,the difference was not statistically significant efficacy, adverse reactions were similar to a degree light, extrapyramidal reactions to the main difference between the two groups was not significant. Conclusion Risperidone orally disintegrating tablets has better curative effect, fewer side effects and better compliance in the treatment of schizophrenia.